The increasing incidence of genetic and rare diseases is a major factor driving revenue growth in the Antisense ...

Biogen has pointed to an early readout from a small phase 1 trial as evidence that its antisense oligonucleotide salanersen could help children with spinal muscular atrophy (SMA) who are still ...

Ultragenyx Pharmaceuticals' GTX-102 earns FDA Breakthrough status after early data shows sustained progress in Angelman syndrome patients.

Panelists discuss how exciting ongoing research efforts are expanding similar gene therapy technologies to other muscular ...

A journey through the FDA’s newly released complete response letters gave glimpses into the journeys to market for Eli ...

Once dismissed as “junk,” a group of RNA molecules has been found to help regrow damaged nerves in mice in new research. The ...

Biogen has been trying to build up its R&D pipeline as it faces increased competition for its biggest-selling products like ...

Biogen Inc. (NASDAQ:BIIB) is one of the most undervalued US stocks according to analysts. On June 25, Biogen announced ...

Phase 3 Aspire study enrollment on track to complete in 2025 Aurora study to evaluate GTX-102 in other Angelman syndrome genotypes and ages expected to initiate later this year NOVATO, Calif., June 27 ...

Candida, a type of fungus, can spread throughout the body via the bloodstream, leading to organ damage and sepsis. Recently, ...

Detailed price information for Ionis Pharmaceuticals (IONS-Q) from The Globe and Mail including charting and trades.